Clinical trial sites often open and close rapidly, with 60% ceasing operations within the first year, impacting patient ...
| Clinical development is undergoing a structural shift. Protocols are growing more complex, budgets are shrinking, and ...
GlobalData on MSN
MSD and Eisai to end Phase III LEAP-012 trial for unresectable HCC
Merck & Co (MSD) and Eisai are set to discontinue their Phase III clinical trial for unresectable, non‑metastatic ...
7h
'We don’t have time': Parents of 4-year-old with rare disorder urge FDA to reconsider drug denial
The FDA denied approving DCA to treat a rare disorder called PDCD. The Higbees are urging the agency to reconsider.
Ministers and the NHS have repeatedly said one in five children leave primary school obese—but data obtained by Full Fact ...
Significant increases in risk were observed for all autoimmune diseases except Graves disease and autoimmune hepatitis ...
The software includes scattergrams comparing attempted vs achieved corrections, which can be used to refine surgical ...
It was the best of interviews, it was the worst of interviews. At times I was born aloft on the wings of enlightenment, other ...
At an interim analysis of the phase 3 LITESPARK-011 trial (NCT04586231), the oral combination of belzutifan (Welireg) plus ...
Patients with stroke who receive intra-arterial thrombolysis after thrombectomy are more likely to achieve superior 90-day ...
Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...
Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback